New hope for hard-to-treat head and neck cancer: drug combo enters phase 2 trial
Disease control
Not yet recruiting
This study tests whether adding ficerafusp alfa to the immunotherapy nivolumab can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that has stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will take part. The goal is …
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC